Identification and functional analysis of sequence variants in the long control region and the E2 open reading frame of bovine papillomavirus type 1 isolated from equine sarcoids  by Nasir, L. et al.
7) 355–361
www.elsevier.com/locate/yviroVirology 364 (200Identification and functional analysis of sequence variants in the long control
region and the E2 open reading frame of bovine papillomavirus type 1
isolated from equine sarcoids
L. Nasir ⁎, E. Gault, I.M. Morgan, G. Chambers, V. Ellsmore, M.S. Campo
Division of Pathological Sciences, Institute of Comparative Medicine, University of Glasgow Faculty of Veterinary Medicine,
Bearsden Road, Glasgow G61 1QH, Scotland, UK
Received 29 November 2006; returned to author for revision 10 January 2007; accepted 12 February 2007
Available online 6 April 2007Abstract
BPV-1 DNA is the predominant viral type detected in equine sarcoids and represents the only reported natural cross species infection of
papillomaviruses. In this study, nucleotide variations in the LCR and the E2 regions of equine sarcoid-associated BPV-1 were characterised by
sequence analysis. Variants particular to sarcoid BPV-1 were identified in both the LCR and E2 sequence. The functionality of the most common
LCR variant was examined in equine and bovine cells. These studies showed that the activity of the variant LCR was higher in equine cells than
bovine cells; the activity of the variant LCR in the presence of the E2 variant was similar to the reference/wild-type sequences in equine cells,
whereas in bovine cells the variant function was reduced by 50%. These data suggest the viral BPV variants commonly detected in sarcoids have
an enhanced function in equine cells compared to their function in bovine cells.
© 2007 Elsevier Inc. All rights reserved.Keywords: Equine; Bovine; Bovine papillomavirus; BPV-1Introduction
Equine sarcoids are locally invasive, fibroblastic skin
tumours and represent the most common skin tumour in horses,
donkeys and mules worldwide (Jackson, 1936; Ragland et al.,
1970; Pascoe and Summers, 1981). Although not metastatic,
sarcoids can often result in morbidity causing economic loss of
affected animals (Marti et al., 1993) and currently there is no
effective ubiquitous therapy available. The majority of reports
in the literature support the association of the pathogenesis of
the sarcoid with bovine papillomavirus (BPV) types 1 and 2
infection. The papillomaviruses (PVs) belong to a large family
of animal and human PV that normally infect epithelial cells
causing hyperproliferative lesions known as warts, papillomas
or condylomas. Some types of PVs, including BPV types 1 and
2, can also infect fibroblasts and induce fibro-epithelial
tumours, resulting in benign fibropapillomas in cattle.⁎ Corresponding author.
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doi:10.1016/j.virol.2007.02.019Many studies have reported an association with BPV-1/2
infection in sarcoid pathogenesis based on the presence of viral
DNA sequences (Otten et al., 1993; Bloch et al., 1994; Reid et
al., 1994; Martens et al., 2001; Chambers et al., 2003b). We and
others have also shown that many of the BPV viral genes are
expressed in sarcoids (Nasir and Reid, 1999; Carr et al., 2001;
Chambers et al., 2003a), supporting active papillomavirus
infection. Although PVs are normally strictly species-specific,
sarcoids represent the only documented case of natural cross-
species PV infection (Lancaster et al., 1979; Gorman, 1985).
However, there are numerous differences between BPV-1/2
infection in cattle and in horses. Infection by BPV-1/2 in cattle
results in the formation of cutaneous fibropapillomas, benign
tumours with a fibroblastic and an epithelial component,
productive for infectious progeny virus. As is the case for
most PV infections, BPV-induced papillomas regress in
response to an appropriate effector immune response. Although
the precise mechanisms that contribute to the clearance of PV
infected cells are not clear, a cell-mediated immune response is
thought to be the major contributor to the regression of PV-
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1994; Knowles et al., 1996; Frazer, 1996). In contrast with the
normal course of BPV disease in cattle, infection with BPV-1/2
in horses results in sarcoids, lesions which are non-permissive
for virus production (Gorman, 1985), locally aggressive and
non-regressing (Ragland et al., 1970). However, the factors that
contribute to the different outcomes of BPV infection in horses
and cattle have not been investigated.
The long control region (LCR) of PVs play an important
role in the pathogenesis of PV infections since the LCR
functions as the transcriptional control unit of the virus. BPV-1
LCR is approximately 1 kbp in length. Transcriptional control
from the LCR is regulated by a range of cellular factors and
also by the virally encoded early gene product E2, which is
also required for viral DNA replication (McBride et al., 1991).
E2 is a 48-kDa transcriptional factor which regulates tran-
scription by binding as a dimer to its specific recognition
sequence (ACCN6GGT) which is repeated several times within
PV genomes (Ham et al., 1991; Dostatni et al., 1988; McBride
et al., 1989). BPV-1 has 12 sites corresponding to the
consensus sequence and a further 5 closely related sequences
that also bind E2 (Li et al., 1989). Previous studies on PVs
have shown that intra-type sequence variation within the LCR
exists and some LCR variants exhibit altered transcriptional
control, which in turn may affect the pathogenesis and
transforming effects of the virus (Kammer et al., 2000;
Kurvinen et al., 2000; Veress et al., 2001; Scmidt et al.,
2001). Similarly, sequence variation within HPV E2 transcrip-
tional regulatory proteins has also been documented (Hecht et
al., 1995; Veress et al., 1999).
We have previously shown that sarcoids are associated with
sequence variants within the BPV-1 major transforming gene
E5 and most of the sequence variation is associated with an
increase in codon usage in mammalian cells (Chambers et al.,
2003a; Nasir and Reid, 2006). Naturally occurring sequence
changes within the BPV-1 LCR and/or the E2 protein may at
least partially be responsible for differences in the outcome of
BPV-1 infection in horses compared to cattle. In the present
study, sequence variation within the LCR of BPV-1 was
determined in a panel of sarcoids and compared with cattle
tumours and the transcriptional activity of the most common
variants evaluated.
Results
BPV-1 LCR sequence variants
In this study, the nucleotide sequence of BPV-1 LCR (nts.
7252–7947) was determined from 35 equine sarcoid samples
(comprising 9 British and 26 Swiss samples) and 14 British
bovine tumour samples. The expected product of 790 bp was
detected in all tumours examined, thereby excluding the
presence of deletion variants as reported for HPV 16 (Chan et
al., 1992; Tornesello et al., 2000). In equine sarcoids, none of
the BPV-1 LCR sequences were identical to the reference
sequence. Different combinations of sequence changes were
termed variants.In equine sarcoids, a total of 5 different BPV-1 LCR
sequence variants was identified as shown in Fig. 1; variant I
was identified in two samples; variant II in 23 samples; variant
III and V were detected in one sample each and variant IV in
eight samples. Variants I, II and V were detected only in the
Swiss sarcoids and variants III and IV in British sarcoids.
Analysis of the bovine tumour samples showed that 3 samples
contained sequences identical to the reference LCR. Seven
contained variant IV and the remaining 4 samples contained a
novel variant not detected in sarcoids, variant VI (Fig. 1).
Five of the six variants (I, II, III, IV, VI) showed identical
sequence changes within the E2 binding sites, BS6 and BS8
compared to the reference LCR; all five variants contained
nucleotide substitutions G7595 T and A7598C within BS6, and
a G7642A substitution in BS8. A further single nucleotide
change (C7785G) was detected in variant V, within BS10. As
shown in Fig. 1 the reference LCR sequence was found to differ
from the STD sequence by several nucleotides. In particular,
variation was identified within the BS8 E2 site of the reference
LCR, ACCGATATGGAT.
BPV-1 E2 sequence variants
As transcriptional control from the LCR is regulated by the
virally encoded early gene product E2, and BPV-1 LCR
sequence variation was identified within E2 binding sites, we
sought to determine whether sarcoids were associated with E2
sequence variants. To this end, the BPV E2 ORF was PCR
amplified from six Swiss sarcoids and four British sarcoids. All
10 samples contained identical E2 sequences, with 9 nucleo-
tides consistently different from the BPV-1 E2 reference
sequence, resulting in 5 amino acid substitutions (Table 1).
Three of the changes (L53V, A104S, N136K) occur within the
transactivation domain of E2 (residues 1 to 210) and two
(T313I, I314T) within the ‘hinge’ region (residues 210–324)
(Table 1).
BPV-1 LCR transcriptional activity
BPV-1 LCR variant II was the most commonly detected
sequence in equine sarcoids and was not detected in any of the
14 bovine samples analysed. This variant also contains the
majority of the nucleotide changes present in the additional
variants with a few exceptions (Fig. 1). We therefore sought to
address the transcriptional activity of variant II in relation to the
reference LCR. The full-length LCR sequences were cloned
into the pGL3 vector and transfected into EqPalF and BovPalF
cells. Empty pGL3basic vector was used as a negative control
and consistently gave low background activity in either cell type
(data not shown). As shown in Fig. 2, the transcriptional activity
of the variant LCR was not significantly different from the
activity of the reference LCR in BovPalFs, however in EqPalFs,
the transcription activity of the variant LCR was approximately
twice as high as that of the reference LCR.
The transcriptional regulator E2 binds to E2 binding sites
within the LCR inducing a dose-dependent transactivation
(Kovelman et al., 1996; Morgan et al., 1998). To assess whether
Fig. 1. Sequence alignment of the six BPV-1 LCR variants (I–V), identified in 35 sarcoid tumours, 14 bovine tumours and the reference and STD BPV-1 LCR sequences. E2 binding sites (BS) are underlined. Dashes (–)
indicate sequence similarity with the reference LCR. The numbers at the end of the sequences indicate howmany times each sequence was isolated from equine sarcoids tumours and the numbers in brackets indicate how













Fig. 3. Immunoblot of reference and variant E2 protein expression in BovPalF
cells using actin as a control (lower panels).
Table 1
Nucleotide variation associated with BPV-1 reference E2 and sarcoid-associated
variant E2 in equine cells
Reference E2 Variant E2
Nucleotide AA Nucleotide AA
2764CTT2766 L (53) 2764GTC2766 V
2917GCA2919 A (104) 2917TCA2919 S
3013AAT3015 N (136) 3013AAG3015 K
3543ACC2545 T (313) 3543ATC2545 I
3546ATC3548 I (314) 3546ACC3548 T
Numbers in parentheses refer to the E2 amino acid residue.
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to the same extent as the reference LCR, it was first necessary to
determine whether reference and variant E2 proteins were
expressed in similar amounts. To this end, the reference and
variant E2 expression vectors were transfected into EqPalF cells
and E2 protein detected by Western blot analysis. These studies
demonstrated that the variant E2 protein is expressed at similar
levels to the reference E2 in either cell type (Fig. 3).
To determine whether the transcriptional activities of the
variant LCR and/or variant E2 differed from the activities of
reference LCR and E2 in EqPalF or BovPalFs, cells were co-
transfected with either variant or reference LCR plasmid vectors
in the presence of either reference E2 or variant E2 expression
vectors (titrations experiments in both cell types determined that
a concentration of 0.01 μg of E2 expression plasmid was
optimal for transcriptional activation; data not shown). As
shown in Fig. 4, in BovPalFs, reference E2 induced approxi-
mately a 6- to 7-fold increase in the activity of both reference
and variant LCR, whereas variant E2 transactivated reference
and variant LCR by only 5- and 3-fold, respectively. In contrast,
in EqPalFs all the combinations of reference/variant LCR/E2
lead to similar levels of transcriptional transactivation; approxi-
mately 3-fold.
Discussion
Currently little is known about the natural changes in BPV-1
DNA that might contribute to BPV-1 infection in horses and the
development of sarcoid tumours. The aim of the present study
was to determine sequence variation within the transcriptional
regulatory unit, the LCR, and the E2 transcriptional activator of
BPV-1 in equine sarcoids. To this end, we analysed the LCRFig. 2. Luciferase activity under the control of the BPV-1 reference or variant
LCR in BovPalFs and EqPalFs. Results are expressed as fold activation over
reference LCR activity.from a panel of equine sarcoids and bovine tumours containing
BPV-1 DNA. Of the 6 BPV-1 LCR variants identified in this
study, variant II was the most prevalent in horses, accounting for
approx. 66% of all infections. Several studies on human
papillomaviruses have shown the presence of sequence changes
within HPVs. HPV intratypic variation has most extensively
been studied for HPV-16 and such studies have demonstrated
that variation within the transcriptional regulatory sites of
papillomaviruses can result in enhanced activity of the promoter
(Dong et al., 1994; Chen et al., 1997; Veress et al., 1999),
thereby potentially facilitating tumour progression. Similarly,
some variants have been shown to be associated with more
aggressive clinical behaviour (Kurvinen et al., 2000). Of the six
variants identified in the present study, all contained sequence
changes within known E2 binding sites (Li et al., 1989).
Interestingly, BS8 in the reference LCR differs from the BS8 in
the STD BPV-1 sequence. Whilst we have not tested the
functionality of this binding site, a similar variation within the
BS2 BPV-4 LCR has previously been reported (ATCC-
CATTCGGT) and the site has been shown to be functional
(Jackson and Campo, 1991, 1995; Morgan et al., 1998).
Five variants (1, II, III, V, VI) also show changes within
predicted Tst-1 binding sites (AXXXXT, GXXXXT). Whilst
little is known about Tst-1 transcription factors in PV
infections, Tst-1 has been shown to activate the long control
region of the epidermis-specific human papillomavirus 1A
(HPV-1A) (Andersen et al., 2000). No additional changes inFig. 4. Transcriptional activation of reference or variant LCR in the presence of
0.01 μg of reference or variant E2. Results are expressed as fold activation over
LCR activity in the absence of E2.
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in the region under investigation.
The functional analysis of common equine variant, LCR II
compared to the reference LCR in bovine and equine cells (Fig.
2), suggests that the sequence differences observed in the
variant LCR have a discernible effect on LCR functionality in
equine cells but not bovine cells. Since none of the 14 bovine
samples analysed harbour variant II, and only one variant,
namely variant IV, is found in both horses and cattle, we
propose that BPV-1 genomes with variant II LCR sequences
preferentially infect horses and are maintained within equids.
We also analysed sequence variation within the BPV-1 E2
ORF from a subset of sarcoids. Strikingly all sequenced isolates
were identical, but different from reference E2, suggesting that
BPV-1 exhibits low genetic diversity within the E2 region, as
has been reported for HPV-16 E2 (Veress et al., 1999). These
sarcoid associated variants may contribute to altered function in
the equine cells. The BPV-1 E2 protein consists of three
domains comprising an N-terminal transactivation region
(residues 1 to 210) followed by a ‘hinge’ region (residues
210–324) and a carboxy terminal DNA binding dimerisation
domain (residues 325 to 410) (Giri and Yaniv, 1998; Haugen et
al., 1998; McBride et al., 1989). Three changes were detected in
the transactivation domain of sarcoid-associated E2, none of
which occur at known critically important functional residues
(Brokaw et al., 1996; Breiding et al., 1996). Two amino acid
changes were also identified within the unstructured hinge
region of E2. Variation within this region has also been reported
for both HPV-18 (Hecht et al., 1995) and HPV-16 E2 (Eriksson
et al., 1999).
Transcriptional analyses of the E2 variants showed that in
bovine cells, variant E2 transactivates both variant and
reference LCR approx. 30–50% less than the reference E2,
however in equine cells, no such difference is seen and all
combination between variant/reference E2 and variant/reference
LCR show similar transcriptional activities (Fig. 4). Thus,
whereas the changes in E2 and LCR variants from sarcoids are
detrimental in bovine cells, they have no discernible effect in
equine cells. Variant LCR shows higher transcriptional activity
in equine cells than reference LCR, but this difference is
obscured by the transactivation effect of E2. Although we report
here differences between the variant and reference E2 proteins
in regulation of transcription, the differences described are
unlikely to be the major factor contributing towards the ability
of BPV-1 to infect and be maintained in equine cells. However,
E2 has other functions including the ability to replicate the viral
genome in association with the E1 protein, and also in
segregating the viral genome by associating with chromatin
during mitosis (Yang et al., 1991; Skiadopoulos and McBride,
1998). These other properties of E2 may be altered in the
variants described and will be tested in the future. It is possible
that a host of small changes in the sarcoid-isolated BPV-1
genomes contribute to the pathogenesis of sarcoids, for
instance, we have previously described increased codon usage
for E5 protein in sarcoids (Chambers et al., 2003a) and in
conjunction with other small alterations such as those reported
here the overall effect may be the ability of BPV-1 genomes tobe maintained in equine cells. This requires to be evaluated in
future studies.
Nucleotide variation in sarcoid BPV-1, both silent and
leading to amino acid changes have previously been reported by
us in the BPV-E5 sequence (Reid et al., 1994; Chambers et al.,
2003a). Others have also found BPV nucleotide differences in
sarcoids (Trenfield et al., 1985; Angelos et al., 1991). However,
one report suggests absolute homology between the BPV E5
sequences in sarcoids and the published bovine BPV sequence
(Carr et al., 2001). Similarly, Otten et al. (1993) reported
identical sequence variants in both cattle and horses. However,
in the latter study short regions of the BPV genome were
analysed. The finding of BPV variants in randomly collected
sarcoid samples from two different geographical locations leads
us to propose that sarcoids are associated with variant BPV-1
genomes that preferentially infect horses and are maintained
within equids. The mechanism by which the disease is
transmitted is not known although evidence suggests that
contact with affected animals increases the likelihood of disease
(Reid et al., 1994) and face flies (Muscus autumnalis) may act as
a vector (Kemp-Symonds, 2000). There is currently no
epidemiological evidence to support cattle to horse transmission.
Material and methods
Samples
In this study, a total of 35 equine sarcoid samples was used.
The tumours were archival samples collected from horses
treated by collaborating veterinary practices in the UK or
donated by Dr. Eliane Marti of the University of Berne,
Switzerland and hence are representative of BPV-1 infection in
two geographically distinct areas. Tissue sections (either frozen
or paraffin-fixed as appropriate) were cut from all samples and
stained with haematoxylin and eosin and re-evaluated by a
pathologist at the University of Glasgow Faculty of Veterinary
Medicine to confirm the original diagnosis. In addition, DNA
samples from a total of 14 BPV-1 positive bovine papillomas
(13 cases) and bovine bladder cancer (1 case) from archival
samples from the UK were also analysed.
Cell lines
Bovine (BovPalF) and equine (EqPalF) fetal palate fibro-
blasts were maintained in culture in the presence of DMEM
medium supplemented with 10% fetal calf serum.
PCR amplification of BPV-1 LCR and E2
PCR amplification of the LCR was carried out using primers
BPVLCRF (5′ cggtacacatcctgtccagcat 3′ corresponding to
BPV-1 nts. 7211–7232) and BPVLCRR (5′ gatggtgtgattattgt-
taac 3′ corresponding to BPV-1 nts. 21–1) which amplify a 790-
bp product. Reactions were performed in the presence of Pfu™
DNA polymerase (Promega, UK), according to the manufac-
turer's instructions. Cycling conditions were as follows: 1× at
94 °C for 5 min, followed by 35 cycles of 94 °C for 1 min, 56 °C
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10 min. PCR amplification of the E2 ORF was performed using
primers BPVE2F (5′ cctgattgacgaggaggagg 3′ corresponding to
BPV-1 nts. 2576–2595) and BPVE2R (5′ ccatagatttggcatagta-
cacc 3′ corresponding to BPV-1 nts. 3893–3871) which amplify
a 1.3 kbp product. Reactions were performed in the presence of
Pfu™ DNA polymerase (Promega, UK), according to the
manufacturer's instructions. Cycling conditions were as fol-
lows: 1× at 94 °C for 5 min, followed by 30 cycles of 94 °C for
1 min, 59 °C for 1 min, 72 °C for 1 min and a final extension of
72 °C for 10 min. Plasmids containing the entire BPV-1 or
BPV-2 genomes isolated from Scottish bovine penile and skin
papillomas, respectively (Campo et al., 1981), were used as
reference sequences. In all the PCR experiments, negative
controls without a DNA template were also included. The PCR
products were subjected to DNA sequence analysis.
DNA sequencing
Viral genomic DNA PCR products were purified using a
Qiagen mini-prep clean-up kit and subjected to sequence
analysis. Sequencing reactions were performed using the
Applied Biosystems Big Dye terminal sequencing kit and
sequencing performed on an ABI 3100 automated sequencer.
Prior to comparative analysis with the ClustalW server provided
by EMBNet, the data from all sequences were evaluated using
Chromas (Version 1.44) analysis software. All PCR reactions
used for sequencing were performed twice in duplicate to
eliminate PCR-induced errors or sequencing errors. In every
sequencing run, reference BPV-1 and BPV-2 genomes (pre-
pared from the plasmid templates as above) were included.
Sequences from the sarcoid products were compared to the
reference BPV sequences.
Plasmid vectors and transient transfections
The following primers were used to amplify the complete
BPV-1 LCR (nts. 7132 to 90); LCRF 5′cagaaggtaagtcaactg 3′,
corresponding to nts. 7132–7149 of BPV-1 and LCRR 5′
cagaccccggttttcac 3′ corresponding to nts. 74–90 of BPV-1.
The BPV-1 variant LCR (variant II) was amplified from a DNA
sample known to contain the variant sequence and was cloned
upstream of the Firefly luciferase reporter gene using the pGL3
vector system (Promega, UK). The reference LCR was PCR
amplified from BPV-1 plasmid DNA and subcloned into the
pGL3 luciferase reporter vector. Similarly, the BPV-1 variant
E2 ORF and reference E2 ORF were PCR amplified from a
DNA sample known to contain variant E2 and the reference
BPV-1 plasmid, respectively. Products were cloned into the
pTARGET expression vector (Promega, UK) to drive consti-
tutive expression from the human cytomegalovirus (CMV)
immediate-early enhancer/promoter. Transfections were carried
out using Lipofectamine Reagent (Invitrogen, UK) in the
presence of Plus reagent (Invitrogen, UK) following the
manufacturer's recommended protocol. Each assay was
performed in triplicate a minimum of two times. For each
assay, 2×105 cells were seeded into 6-well plates andtransfected the following day when the cells reached a
confluence of approximately 40–50%. All transfections were
performed in duplicate three times. Cells were transfected with
1 μg of reference LCR or 1 μg of variant LCR vector in the
presence of serial dilutions of either reference E2 or variant E2
expression vectors ranging from 1 μg to 0.01 ng. Briefly, 1 μg
plasmid DNAwas diluted in the presence of 100 μl serum-free
media and precomplexed with 6 μl Plus Reagent for 15 min at
RT. About 4 μl Lipofectamine diluted in 100 μl serum-free
media was then added to the precomplexed DNA and the
solution incubated at RT for a further 15 min. Cells were then
incubated in the presence of the DNA-Plus–Lipofectamine
complexes at 37 °C at 5% CO2 for 3 h. The medium was then
replaced with fresh growth medium and cells were incubated
for a further 48 h prior to harvesting. Luciferase Reporter
assays were performed according to the manufacturer's
protocol (Promega, UK). To account for transfection efficien-
cies, the protein concentration for each transfection was
determined. To determine E2 protein expression, whole cell
extracts from transfected cells lysed in denaturation buffer
were analysed for E2 protein by immunoblotting using a
BPV-1 anti-E2 antibody kindly provided by E. J. Androphy
(Androphy et al., 1987).
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